Source: PreveCeutical Medical Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PreveCeutical Medical (PREV) has signed a $3 million credit facility agreement with its CEO and Chair, Stephen Van Deventer, and its former president and director, Kimberly Van Deventer
  • The convertible credit facility agreement has a simple annual interest of 10 per cent
  • Part of the credit will be used by the company for product development, general corporate, and working capital purposes
  • PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products
  • PreveCeutical Medical Inc. opened the day’s trading at $0.025 per share

PreveCeutical Medical (PREV) has signed a $3 million credit facility agreement.

The agreement is with the company’s Chief Executive Officer and Chair, Stephen Van Deventer, and the company’s former president and director, Kimberly Van Deventer.

On July 18, 2022, the company entered into the convertible credit facility agreement with the two lenders with a simple annual interest of 10 per cent.

Any outstanding principal and accrued interest will be convertible into fully paid and non-assessable common shares in the capital of PreveCeutical at a conversion price of $0.025 per share in accordance with the terms of the agreement.

In line with the agreement, the lenders have consolidated specific outstanding principal and accrued interest for existing credit facilities with the company. They have transferred an aggregate of $2,448,785.75 to the agreement. These credit facilities agreements were terminated effective July 18, 2022.

The proceeds available under the agreement will be used for product development, general corporate, and working capital purposes.

As the lenders are current and/or former directors and executive officers of the company, the agreement constitutes a related party transaction in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural products.

PreveCeutical Medical Inc. opened the day’s trading at $0.025 per share.


More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.